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Several commonly used antituberculous drugs are potentially hepatotoxic and can cause severe, and even fatal, hepatitis. Apart from an estimated hepatotoxicity of 1%-0.1% [1, 2] , the standard preventive treatment for latent tuberculosis infection (LTBI) with 6 months of isoniazid (6H) therapy often results in poor compliance. Less hepatotoxic preventive regimens of shorter duration that are not affected by isoniazid resistance were therefore sought [3] [4] [5] [6] . In 1998 and 2000, the Centers for Disease Control and Prevention (CDC) and the American Thoracic Society (ATS) recommended a preventive treatment with 2 months of rifampin and pyrazinamide (2RZ) therapy [7] [8] [9] . Severe (and sometimes fatal) hepatitis has since been associated with 2RZ therapy [10] [11] [12] [13] , and studies found severe hepatotoxicity in 5.3%-13% of all patients receiving 2RZ therapy [14] [15] [16] [17] [18] . Toxicity was not expected because, in the 1970s and 1980s, the rates of drug-induced liver dysfunction did not increase when pyrazinamide was added to curative regimens containing isoniazid and rifampin [19] [20] [21] . In August 2003, after 48 reports confirmed severe liver injury related to 2RZ therapy, including 11 deaths (23% of the reports), the ATS and the CDC advised that 2RZ therapy should generally not be offered to persons with LTBI [22] .
This retrospective cohort study compared rates of hepatotoxic adverse effects among patients in The Netherlands receiving either the preventive 2RZ or 6H regimens or the 2-month intensive-phase tuberculosis (TB) treatment, combining at least isoniazid, rifampin, and pyrazinamide (2HRZ+). The goal was to determine relative rates of hepatotoxicity and whether 2RZ pre-ventive treatment was more toxic than 2RZ therapy as part of a triple-or quadruple-drug curative regimen [17, 23] .
METHODS
Design of the study. Data on 2RZ preventive treatment of LTBI in patients у15 years old were collected in a partly prospective and partly retrospective cohort study. Prospectively, all 42 TB control departments of municipal health services in The Netherlands were requested to complete a form for each patient who began 2RZ therapy from January 2000 through December 2001. Retrospectively, 2 comparison groups were selected from The Netherlands Tuberculosis Register (NTR), one consisting of all patients who received a diagnosis of TB and the other consisting of all patients who began 6H treatment for LTBI. Each patient in the 2RZ cohort was randomly matched with a maximum of 4 patients selected from those registered with 6H preventive treatment and a maximum of 4 patients selected from those registered with 2HRZ+ curative treatment by sex, age (in 5-year groups), and Dutch or foreign nationality. Each matching patient could be selected from the NTR only once for each course of treatment. A 1:3 match ratio was calculated as sufficient to provide (at a significance level of .05) 80% power to detect a 5-fold increase in hepatotoxicity, compared with the 1% rate of severe hepatotoxicity related to isoniazid [1] . However, 4 matches were made to compensate for those patients with missing or incomplete files. Patients receiving less than one-half of their recommended course of treatment because of reasons other than hepatotoxicity were excluded from the study.
Data collection. For all 3 patient groups, data were collected on demographic characteristics, reason for receiving a tuberculin skin test, liver enzyme levels, drug dosage, body weight, possible comedication or comorbidity, reported use of alcohol, completion of treatment, and adverse effects. Identical forms and definitions were used for all 3 patient groups. Physicians in TB control departments completed forms for the 2RZ group. For both of the other groups, forms were completed by one of the investigators (S.K.) on the basis of information in the patient's file.
Outcomes. The primary outcome was severe hepatotoxicity, defined as an increase of the serum concentration of either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) to 15 times the upper reference level reported by the laboratory, irrespective of any previous measurement. Secondary outcomes were mild hepatotoxicity (defined as an increase of AST or ALT serum levels from normal to between normal and 5 times the upper reference values), and discontinuation of treatment due to hepatotoxicity. If ALT or AST levels had not been determined and the patient had not discontinued treatment, severe or mild hepatotoxicity was assumed not to have occurred. Patients with mild hepatotoxicity were considered to still be at risk for developing severe hepatotoxicity, but not vice versa.
Statistical analysis. Data were entered into EpiInfo software, version 6.04 (CDC) [24] . All entries were visually checked against the forms. A random sample of 10% of the records was entered twice and validated, resulting in a 100% match. Data were analyzed using Stata software, version 6 (Stata). To allow adjustment for confounding by the weight-adjusted dosage of drugs, a dose of pyrazinamide was categorized as low if р19.9 mg/kg, normal if 20.0-29.9 mg/kg, and high if у30.0 mg/kg; a dose of rifampin was categorized as low if р7.99 mg/kg, normal if 8.0-9.99 mg/kg, and high if у10.0 mg/kg; and a dose of isoniazid was categorized as low if р3.99 mg/kg, normal if 4.0-4.99 mg/kg, and high if у5.0 mg/kg. Crude and adjusted relative risks were expressed as ORs and were calculated by logistic regression analysis. Because matched sets could vary in the number of controls, calculations included adjustment for matching factors [25] . Covariates for the adjusted ORs were age, sex, and weight-adjusted drug doses. Other variables (nationality, HIV infection status, reported alcohol use, possibly hepatotoxic comedication) were tested for potential confounding, defined as a change in OR for the treatment group comparison of у10%. The weight-adjusted drug doses were fitted with the records of patients for whom the body weight was not recorded as a separate stratum. Interaction for these variables was assessed before and after exclusion of these incomplete records. Regarding the 2RZ and 6H groups, the strata compared low, normal, and high weight-adjusted doses for rifampin versus isoniazid and for pyrazinamide versus isoniazid, respectively. The P values were based on the likelihood ratio test for excluding the variable of interest from the model, except in stratified models, for which P values were based on the Wald test [26] . A 2-sided P value of !.05 was considered to be statistically significant.
RESULTS

Comparison groups.
Preliminary results for all 2RZ patients in The Netherlands known to us were reported previously [27] . During the 2 years studied, 2840 patients aged у15 years started treatment for LTBI, of whom 216 (7.6%) used 2RZ; we received 166 forms for these patients (response rate, 77%). Initially, 656 patients in the 6H group and 491 patients in the 2HRZ+ group could be matched to the 166 patients for whom we received forms; of these, 528 patients in the 6H group and 410 patients in the 2HRZ+ group met inclusion criteria for analysis (table  1) . The 2RZ and 6H groups were well matched in age, sex, and nationality (table 2). Patients in the 2HRZ+ group were older, more often male, and more often of non-Dutch nationality than were patients in the 2RZ group. Compared with the 2RZ group, liver enzyme levels had been tested more often in the patients in the 2HRZ+ group but less often in patients in the 6H group, primarily because of more baseline testing in the 2HRZ+ group and less testing during treatment in the 6H group (table 2) . Reported alcohol use and abuse, HIV infection, and potentially hepatotoxic comedication were slightly more common in the 2HRZ+ group but were rare overall. Considerably more patients in the 2HRZ+ group were using methadone than were patients who were receiving preventive treatment of LTBI. The mean weight-adjusted isoniazid, rifampin, and pyrazinamide doses showed little difference among the treatment groups. All mean weight-adjusted doses were slightly below the recommended dose, except for pyrazinamide in the 2RZ group. Eighty-three percent of patients in the 2RZ group completed preventive therapy, as did 88% in the 6H cohort; 93% of the patients in the 2HRZ+ group completed the intensive phase of TB treatment. Severe hepatotoxicity. Severe hepatotoxicity occurred in 14 (8.4%) of 166 patients in the 2RZ group (95% CI, 4.7-13.7), versus 18 (3.4%) of 528 patients in the 6H group (95% CI, 2.0-5.3;
) and 14 (3.4%) of 410 patients in the P p .012 2HRZ+ group (95% CI, 1.9-5.7;
; table 3). Among P p .016 525 patients tested during or just after treatment, hepatotoxicity was severe in 14 (15.4%) of 91 patients in the 2RZ group, 18 (8.3%) of 218 in the 6H group, and 14 (6.5%) of 216 in the 2HRZ+ group. Treatment was discontinued in 13 of 14 such patients in the 2RZ and 2HRZ+ groups, and in 15 of 18 patients in the 6H group (table 4) . Of the 14 patients in the 2RZ group, 8 (57%) had transaminase levels of 200-1000 U/L, 4 (29%) had levels of 1000-2000 U/L, and 2 (14%) had levels of 2560 U/L and 5553 U/L, respectively; 16 (89%) of the 18 patients in the 6H group and 13 (93%) of the 14 patients in the 2HRZ+ group had levels of 200-1000 U/L; 1 patient in the 6H group (6%) and 1 patient in the 2HRZ+ group (7%) had levels of 1000-2000 U/L, and 1 patient in the 6H group (6%) had a level of 2467 U/L.
Severe hepatotoxicity among women receiving 2RZ occurred approximately twice as often as among men receiving the same regimen, but the association with sex was not significant (table  3) . Toxicity strongly increased with age among patients receiving 6H therapy but was not associated with age among patients receiving 2RZ or 2HRZ+ therapy. There was no association with the weight-adjusted dose of any drug, except for pyrazinamide in the 2RZ group only; in this group, 3 (37.5%) of 8 patients with severe hepatotoxicity had received 30 mg/kg or more, compared with 6 (5.7%) of 105 patients without severe hepatotoxicity ( ). P p .001 The crude relative risk (expressed as an OR) for severe hepatotoxicity among patients receiving 2RZ therapy, compared with patients receiving 6H therapy, was 2.61 (95% CI, 1.26-5.39;
; table 5). Adjustment for differences in age, sex, P p .012 and weight-adjusted dose of pyrazinamide versus isoniazid and of rifampin versus isoniazid had little effect (OR, 2.77). However, the ORs for patients receiving 2RZ therapy, compared with patients receiving 6H therapy, differed among the age strata. The analysis was therefore repeated seperately for 3 age strata: 15-24 years, 25-34 years, and 35-54 years ( , P p .043 by x 2 test for interaction). A strongly and significantly increased risk of severe hepatotoxicity was found among patients receiving 2RZ therapy, compared with that among patients receiving 6H therapy, if they were !25 years old, but not if they were older. There was no other significant interaction, nor was there , by x 2 test for interaction). The P p .049 analysis was therefore repeated for 2 strata of pyrazinamide dose separately: !30 mg/kg and у30 mg/kg in the 2RZ and 2HRZ+ groups (
, by x 2 test for interaction; table 6). P p .031 Results showed a strongly increased risk of severe hepatotoxicity among patients in the 2RZ group, compared with those in the 2HRZ+ group, if the weight-adjusted dose of pyrazinamide was у30 mg/kg (adjusted OR, 11.5) but showed none for lower doses (adjusted OR, 1.06). There was no other interaction or confounding by any of the other variables mentioned.
To further explore the effect of the pyrazinamide dose, the analysis presented in table 6 was repeated after recoding as "high" all patients in the 2RZ group with weight-adjusted doses of у20 mg/kg (i.e., it was repeated with different cut-off points for high dose in the treatment groups, in accordance with international recommendations). According to this analysis, the crude ORs for treatment groups in the low or normal and high stratas of relative pyrazinamide dose were similar (2.23 and 2.13, respectively; , by x 2 test for interaction). If the P p .974 pyrazinamide dose, coded in this way, was fitted as a covariate in a multivariate model that also adjusted for age, sex, and weight-adjusted rifampin dose, the adjusted OR for treatment groups (2RZ group vs. 2HRZ+ group) was 2.69 (95% CI, 0.98-7.33;
). P p .049 Mild hepatotoxicity. Excluding patients with cases of severe hepatotoxicity, mild hepatotoxicity was reported in 10 (6.6%) of the remaining 152 patients in the 2RZ group (95% CI, 3.2-11.8), in 23 (4.5%) of the 510 patients in the 6H group (95% CI, 2.9-6.7;
), and in 33 (8.3%) of 396 patients P p .294 in the 2HRZ+ group (95% CI, 5.8-11.5;
; table 4). P p .596 Among 479 patients tested during or just after treatment, mild hepatotoxicity occurred in 10 (13.0%) of 77, in 23 (11.5%) of 200, and in 30 (16.3%) of 202 patients, respectively. These differences were not significant. In all groups, !1% of the patients discontinued treatment because of mild hepatotoxicity (table 4) , and mild hepatotoxicity showed no association with age, sex, or relative drug dose (data not shown).
DISCUSSION
Severe hepatotoxicity occurred more often among patients in the 2RZ group than among patients in the 6H group, especially in those !25 years old. It was likewise more frequent among patients in the 2RZ group than among patients receiving treatment with 2HRZ+, especially if the weight-adjusted dose of pyrazinamide was у30 mg/kg. Even if patients in the 2RZ group received pyrazinamide in the advised dose of up to 20 mg/kg and those in the 2HRZ+ group received 30 mg/kg, treatment with 2RZ was more hepatotoxic. We found no significant dif- NOTE. 2HRZ+, 2 months treatment for active tuberculosis with at least isoniazid, rifampin, and pyrazinamide; 2RZ, 2 months of rifampin-pyrazinamide preventive treatment; 6H, 6 months of isoniazid preventive treatment.
a Data does not include patients who experienced cases of severe hepatotoxicity. Table 5 . Crude and age-adjusted relative risks of severe hepatoxicity for patients with latent tuberculosis infection receiving 2 months of rifampin-pyrazinamide preventive treatment (2RZ) and those receiving 6 months of isoniazid preventive treatment (6H).
Model, treatment Crude OR (95% CI) P Adjusted OR (95% CI) P Unstratified 6H NOTE. Strata for relative pyrazinamide dose were as follows: low pyrazinamide (Z); low isoniazid (H), normal Z; normal H, high Z; high H. Strata for relative rifampin dose were: low rifampin (R); low isoniazid (H), normal R; normal H, high R; high H. Relative doses were weightadjusted. Patients with unknown weight were treated as a separate stratum. For definitions of low, normal, and high doses, see Methods.
a Adjusted for age (strata, 15-24 years, 25-34 years, 35-44 years, 45-54 years; , by P p .060 x 2 test for interaction), sex, relative pyrazinamide dose, and relative rifampin dose. b Adjusted for sex, relative pyrazinamide dose, and relative rifampin dose.
ference in the occurrence of mild hepatotoxicity among patients in the 2RZ, 6H, and 2HRZ+ groups. The degree of hepatotoxicity (as measured by the transaminase levels) appeared to be more severe in the 2RZ cohort than in the 6H and the 2HRZ+ cohorts. The proportion of patients who discontinued 2RZ and 6H preventive treatment because of severe hepatotoxicity (7.8% and 2.8%, respectively) almost completely explains the difference in the rates of completion of preventive therapy.
This study agrees with findings reported in the United States of an increased risk of severe hepatotoxicity associated with 2RZ preventive treatment, compared with 6H preventive treatment [15, 18] . The proportion of severe hepatotoxicity found among patients receiving 2RZ therapy in our study lies in the same range as that reported from the United States [14] [15] [16] [17] [18] . An association with sex was consistent with an earlier study [16] , although our result was not statistically significant, possibly because of the relatively small numbers of patients involved. The proportion of severe hepatotoxicity among patients receiving 6H therapy in our study was similar to that among patients receiving 6H therapy in a comparative study of 2RZ and 6H therapy reported in the United States (4.4%) [18] but was higher than that found in another study (1.0%) [15] . The proportion of severe hepatotoxicity found in our 2HRZ+ cohort lies between results reported from the United Kingdom (2.3%) [28] , Canada (2.8%) [29] , and Singapore (5.3%) [30] . Our patient groups were relatively young (mean age ‫ע‬ SD, years, years, and years, for 27.9 ‫ע‬ 10.9
27.0 ‫ע‬ 10.3 30.3 ‫ע‬ 10.2 patients in the 2RZ, 6H, and 2HRZ+ groups, respectively), because Dutch policy excludes persons born before 1945 from receiving a tuberculin skin test. Therefore, our results could be an underestimation, compared with findings reported from the United States [1, 10, 11, [15] [16] [17] [18] . Compared with isoniazid, 2RZ causes considerably more severe hepatotoxic reactions in patients aged !35 years, especially in the 15-24 age group. Because of the well-known increase in the frequency of isoniazid-related hepatitis with increasing age [1, 2] , which is reflected in our data, the relative toxicity of 2RZ is not observed in patients 135 years old, in contrast to the results reported by another study [15] . The difference in severe hepatotoxicity between the 2RZ and the 6H preventive treatments is likely attributable to the different drugs used. Contrary to other findings, previous use of isoniazid did not predispose our patients to hepatotoxicity during 2RZ treatment [27] . However, some Dutch TB physicians, prior to the first ATS/CDC warnings, chose the shorter regimen (2RZ ) for patients with an elevated risk for liver injury (e.g., caused by alcohol abuse). The possible resulting bias will be discussed below.
The difference in severe hepatotoxicity between 2RZ preventive therapy and 2HRZ+ treatment for active TB is puzzling but might reflect a larger intake of alcohol among patients in the 2RZ group [15, 17, 18] , TB-impaired host immunity suppressing hepatotoxic reactions [23] , the dose of pyrazinamide, or an antagonistic role of isoniazid against pyrazinamideinduced hepatotoxicity [16] . Immunogenetic differences contributing to the development of hepatitis induced by antituberculous drugs have been suggested [31] and disputed [32] . Different backgrounds among the patient groups can create confounding factors, such as comorbidity (e.g., HIV infection or hepatitis A, B, or C virus infection). Apart from increasing hepatotoxicity with increasing age for isoniazid, information on possible contributing causes of liver injury induced by antituberculous drugs is conflicting or speculative.
The limitations of this study are that possible confounding and bias cannot be completely eliminated. We controlled for some potential confounders, but others may have arisen. As noted above, bias by indication towards the selection of candidates for 2RZ treatment is possible, because retrospective studies are not randomized. The incidence of severe hepatotoxicity in the 2RZ cohort could thus be overestimated if a proportion of patients higher than that in the 6H group had risk factors for liver injury, such as regular alcohol use or chronic liver disease (e.g., viral hepatitis, alcoholic hepatitis, or cirrhosis). Ascertainment bias could have occurred in our study, because transaminase levels were not determined systematically for all patients. Few cases of severe hepatoxicity would be missed, because they become clinically apparent, but mild hepatotoxicity could go unnoticed. Studies in which transaminase levels are systematically determined may detect hepatoxicity earlier than studies in which levels are usually determined only when clinically indicated, allowing progression to severe hepatitis to be prevented by discontinuation of treatment. Our results, compared with those of the 2RZ studies conducted in the United States [14] [15] [16] [17] [18] , are thus more likely to overestimate, rather than underestimate, severe hepatotoxicity. Ascertainment bias among the 3 cohorts in this study is also possible. More baseline testing among patients in the 2HRZ+ cohort, compared with those in the 2RZ cohort, may have more promptly identified patients who were at risk for severe hepatotoxicity, leading to an underestimate of such cases, and less testing before and during treatment in the 6H cohort, compared with the 2RZ cohort, may have missed patients who were at risk for severe hepatotoxicity, leading to an overestimate of such cases (table 2) . Finally, observer's bias could have occurred, because 2RZ data were reported by physicians in TB control departments, while other data were collected by one of the investigators (S.K.). However, a standardized form was used throughout this study to minimize such bias.
In conclusion, this study confirms that 2RZ preventive treat-ment in predominantly HIV-negative patients with LTBI is more hepatotoxic than both the 6H preventive regimen and the 2HRZ+ treatment for patients with TB. It supports the latest ATS/CDC recommendations that 2RZ therapy generally should not be offered for preventive therapy for LTBI, although rifampin and pyrazinamide can be prescribed for the intensive phase of active TB treatment [22] . Thus, the need to improve preventive regimens remains. In the United States, the shortest advised treatment for LTBI is 4 months of monotherapy with daily rifampin [9] . An alternative recommended by the Joint Tuberculosis Committee of the British Thoracic Society is 3 months of daily isoniazid and rifampin, a regimen supported by study data and experience [33, 34] .
